Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Cash & Equivalents (2022 - 2025)

Coya Therapeutics' Cash & Equivalents history spans 4 years, with the latest figure at $28.1 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 9.52% year-over-year to $28.1 million; the TTM value through Sep 2025 reached $28.1 million, down 9.52%, while the annual FY2024 figure was $38.3 million, 17.51% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $28.1 million at Coya Therapeutics, down from $29.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $38.3 million in Q4 2024 and bottomed at $5.9 million in Q4 2022.
  • The 4-year median for Cash & Equivalents is $30.4 million (2024), against an average of $26.2 million.
  • The largest annual shift saw Cash & Equivalents soared 449.86% in 2023 before it dropped 18.7% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $5.9 million in 2022, then skyrocketed by 449.86% to $32.6 million in 2023, then increased by 17.51% to $38.3 million in 2024, then fell by 26.71% to $28.1 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Cash & Equivalents are $28.1 million (Q3 2025), $29.8 million (Q2 2025), and $35.5 million (Q1 2025).